|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Bee-Choo T, Ho JS and Unverzagt S: Chemotherapy for
advanced gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
|
3
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T,
Herraez-Baranda LA, Xia F, Garg A, Shing M and Tabernero J:
HELOISE: Phase IIIb Randomized multicenter study comparing
standard-of-care and higher-dose trastuzumab regimens combined with
chemotherapy as first-line therapy in patients with human epidermal
growth factor receptor 2-positive metastatic gastric or
gastroesophageal junction adenocarcinoma. J Clin Oncol.
35:2558–2567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yazici O, Sendur MA, Ozdemir N and Aksoy
S: Targeted therapies in gastric cancer and future perspectives.
World J Gastroenterol. 22:471–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Myint ZW and Goel G: Role of modern
immunotherapy in gastrointestinal malignancies: A review of current
clinical progress. J Hematol Oncol. 10:862017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicenter, open-label, phase 1b trial.
Lancet Oncology. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bang YJ, Cho JY, Kim YH, Kim JW, Di
Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T and
Moehler M: Efficacy of sequential ipilimumab monotherapy vs best
supportive care for unresectable locally advanced/metastatic
gastric or gastroesophageal junction cancer. Clin Cancer Res.
23:5671–5678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zitvogel L, Galluzzi L, Smyth MJ and
Kroemer G: Mechanism of action of conventional and targeted
anticancer therapies: Reinstating immunosurveillance. Immunity.
39:74–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramakrishnan R, Huang C, Cho HI, Lloyd M,
Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E and
Gabrilovich DI: Autophagy induced by conventional chemotherapy
mediates tumor cell sensitivity to immunotherapy. Cancer Res.
72:5483–5493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vacchellie E, Aranda F, Eggermont A, Galon
J, Sautes-Fridman C, Cremer I, Zitvogel L, Kroemer G and Galluzzi
L, Kroemer G and Galluzzi L: Trial watch: Chemotherapy with
immunogenic cell death inducers. Oncoimmunology. 3:e278782014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Liu F and Liu L: Prognostic
significance of PD-L1 in solid tumor: An updated meta-analysis.
Medicine (Baltimore). 96:e63692017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
efficacy of pembrolizumab monotherapy in patients with previously
treated advanced gastric and gastroesophageal junction cancer:
Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4:e1800132018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smyth E and Thuss-Patience PC: Immune
checkpoint inhibition in gastro-oesophageal cancer. Oncol Res
Treat. 41:272–280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tabernero J, van Cutsem E, Bang YJ, Fuchs
CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Castro
Salguero HR, et al: Pembrolizumab with or without chemotherapy
versus chemotherapy for advanced gastric or gastroesophageal
junction (G/GEJ) adenocarcinoma: The phase 3 KEYNOTE-062 study. J
Clin Oncol. 37 (Suppl 18):LBA4007. 2019. View Article : Google Scholar
|
|
19
|
Boku N, Ryu MH, Kato K, Chung HC, Minashi
K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, et al: Safety and
efficacy of nivolumab in combination with S-1/capecitabine plus
oxaliplatin in patients with previously untreated, unresectable,
advanced, or recurrent gastric/gastroesophageal junction cancer:
Interim results of a randomized, phase II trial (ATTRACTION-4). Ann
Oncol. 30:250–258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu N, Shen L, Jiang H, Zheng YL, Qian J,
Mao CY, Zhou H and Wang SY: Efficacy and safety of Sintilimab in
combination with XELOX in first-line gastric or gastroesophageal
junction carcinoma (GC/GEJC). J Clin Oncol. 37 (Suppl
15):S40422019. View Article : Google Scholar
|
|
21
|
Shen L, Peng Z and Zhang YQ: Camrelizumab
combined with Capecitabine and Oxaliplatin followed by Camrelizumab
and Apatinib as first-line therapy for advanced or metastatic
gastric or gastroesophageal junction cancer: Updated results from a
multi-center, open label phase II trial. J Clin Oncol. 37 (Suppl
15):S40312019. View Article : Google Scholar
|
|
22
|
Stein A, Moehler M, Trojan J, Goekkurt E
and Vogel A: Immuno-oncology in GI tumours: Clinical evidence and
emerging trials of PD-1/PD-L1 antagonists. Crit Rev Oncol Hematol.
130:13–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A,
Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T,
et al: KEYNOTE-585: Phase III study of perioperative chemotherapy
with or without pembrolizumab for gastric cancer. Future Oncol.
15:943–952. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Janjigian YY, Bendell J, Calvo E, Kim J,
Ascieto PA, Sharma P, Ott PA, Peltola KJ, Jaeger D, Evans J, et al:
Check Mate-032: Phase I/II open-label study of safety and activity
of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and
metastatic (A/M) gastric cancer (GC). J Clin Oncol. 34:40102016.
View Article : Google Scholar
|
|
26
|
Le DT, Bendell JC and Calvo E: Safety and
activity of nivolumab monotherapy in advanced and metastatic
gastric or gastroesophageal junction cancer (GC/GEC): Results from
the CheckMate-032 Study. J Clin Oncol. 34:62016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kelly RJ, Lee J, Bang YJ, Almhanna K,
Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee
KW, et al: Safety and efficacy of durvalumab and tremelimumab alone
or in combination in patients with advanced gastric and
gastroesophageal junction denocarcinoma. Clin Cancer Res.
26:846–854. 2020.PubMed/NCBI
|
|
28
|
Ott PA, Hodi FS and Buchbinder EI:
Inhibition of immune checkpoints and vascular endothelial growth
factor as combination therapy for metastatic melanoma: An overview
of rationale, preclinical evidence, and initial clinical data.
Front Oncol. 5:2022015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Terme M, Pernot S, Marcheteau E, Sandoval
F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E
and Taieb J: VEGFA-VEGFR pathway blockade inhibits tumor-induced
regulatory T-cell proliferation in colorectal cancer. Cancer Res.
73:539–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gabrilovich D, Ishida T, Oyama T, Ran S,
Kravtsov V, Nadaf S and Carbone DP: Vascular endothelial growth
factor inhibits the development of dendritic cells and dramatically
affects the differentiation of multiple hematopoietic lineages in
vivo. Blood. 92:4150–4166. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shrimali RK, Yu Z, Theoret MR, Chinnasamy
D, Restifo NP and Rosenberg SA: Antiangiogenic agents can increase
lymphocyte infiltration into tumor and enhance the effectiveness of
adoptive immunotherapy of cancer. Cancer Res. 70:6171–6180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma(RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kamath SD, Kalyan A and Benson AB:
Pembrolizumab for the treatment of gastric cancer. Expert Rev
Anticancer Ther. 18:1177–1187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
A Phase 1/2 Study of Ramucirumab Plus
Nivolumab in Participants with Gastric or GEJ Cancer [EB/OL].
(2018-05-04) [2020-05-08].
|
|
37
|
Bang YJ, Golan T, Lin CC, Kang YK,
Wainberg ZA, Wasserstrom H, Jin J, Mi G, McNeely S, Laing N, et al:
Interim safety and clinical activity in patients (pts) with locally
advanced and unresectable or metastatic gastric or gastroesophageal
junction (G/GEJ) adenocarcinoma from a multicohort phase I study of
ramucirumab (R) plus durvalumab (D). J Clin Oncol. 36:922018.
View Article : Google Scholar
|
|
38
|
Pavlakis N, Sjoquist KM, Martin AJ,
Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ,
Burnell MJ, et al: Regorafenib for the treatment of advanced
gastric cancer (INTEGRATE): A multinational placebo-controlled
phase II trial. J Clin Oncol. 34:2728–2735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus Nivolumab in patients with advanced gastric
(GC) or colorectal cancer (CRC): An open-label, dose-finding, and
dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol.
37 (Suppl 15):S25222019. View Article : Google Scholar
|
|
40
|
Rüschoff J, Dietel M, Baretton G, Arbogast
S, Walch A, Monges G, Chenard M, Penault-Llorca F, Nagelmeier I,
Schlake W, et al: HER2 diagnostics in gastric cancer-guideline
validation and development of standardized immunohistochemical
testing. Virchows Arch. 457:299–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim WH, Gomez-Izquierdo L, Vilardell F,
Chu KM, Soucy G, Santos L, Monges G, Viale G, Brito MJ, Osborne S,
et al: HER2 Status in Gastric and Gastroesophageal Juntion Cancer:
Results of the Large, Multinational HER-EAGLE Study. Appl
Immunohistochem Mol Morphol. 26:239–245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saeki H, Oki E, Kashiwada T, Arigami T,
Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, et
al: Re-evaluation of HER2 status in patients with HER2-positive
advanced or recurrent gastric cancer refractory to trastuzumab
(KSCC1604). Eur J Cancer. 105:41–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Corraliza-Gorjon I, Somovilla-Crespo B,
Santamaria S, Garcia-Sanz JA and Kremer L: New strategies using
antibody combinations to increase cancer treatment effectiveness.
Front Immunol. 8:18042017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bahou C, Love EA, Leonard S, Spears RJ,
Maruani A, Armour K, Baker JR and Chudasama V: Disulfide Modified
IgG1: An investigation of biophysical profile and clinically
relevant fc interactions. Bioconjug Chem. 30:1048–1054. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sulea T, Rohani N, Baardsnes J, Corbeil
CR, Deprez C, Cepero-Donates Y, Robert A, Schrag JD, Parat M,
Duchesne M, et al: Structure-based engineering of pH-dependent
antibody binding for selective targeting of solid-tumor
microenvironment. MAbs. 12:16828662020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C,
Calin GA, Weiner LM and Fan Z: Trastuzumab upregulates PD-L1 as a
potential mechanism of trastuzumab resistance through engagement of
immune effector cells and stimulation of IFNγ secretion. Cancer
Lett. 430:47–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Janjigian YY, Maron SB, Chatila WK,
Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ,
Won E, et al: First-line Pembrolizumab (P), Trastuzumab (T),
Capecitabine (C) and Oxaliplatin (O) in HER2-positive metastatic
esophagogastric adenocarcinoma. J Clin Oncol. 37 (Suppl
4):S40112019. View Article : Google Scholar
|
|
48
|
Catenacci DV, Park H, Uronis HE, Kang YK,
Lacy J, Enzinger PC, Park SH, Lee KW, Ng MCH, Gold PG, et al:
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+
gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). J Clin
Oncol. 36 (15_suppl):S40302018. View Article : Google Scholar
|
|
49
|
Zhuang GF, Tan Y, Zeng JT, Zhang JW, Tang
J, Zeng SP and Qin X: Expression of serum Dickkopf-1 in gastric
cancer patients. Asian Pac J Trop Med. 8:870–872. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wall JA, Klempner SJ and Arend RC: The
anti-DKK1 antibody DKN-01 as an immunomodulatory combination
partner for the treatment of cancer. Expert Opin Investig Drugs.
May 14–2020.doi: 10.1080/13543784.2020.1769065. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eil R, Vodnala SK, Clever D, Klebanoff CA,
Sukumar M, Pan JH, Palmer DC, Gros A, Tamamoto TN, Patel SJ, et al:
Ionic immune suppression within the tumor microenvironment limits T
cell effector function. Nature. 537:539–543. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Patel SA and Minn AJ: Combination cancer
therapy with immune checkpoint blockade: Mechanisms and strategies.
Immunity. 48:417–433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bernstein MB, Krishnan S, Hodge JW and
Chang JY: Immunotherapy and stereotactic ablative radiotherapy
(ISABR): A curative approach? Nat Rev Clin Oncol. 13:516–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang C, Wang X, Soh H, Seyedin S, Cortez
MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, et al:
Combining radiation and immunotherapy: A new systemic therapy for
solid tumors? Cancer Immunol Res. 2:831–838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Checkpoint Inhibitor and Radiotherapy for
Recurrent Gastric Cancer (CIRCUIT) [EB/OL]. (201 8-12-1 8)
[2020-05-08]. https://clinicaltrials.gov.
|
|
57
|
Milhem M, Gonzales R, Medina T, Kirkwood
JM, Buchbinder E, Mehmi I, Niu JX, Shaheen M, Weight R, Margolin K,
et al: Abstract CT144: Intratumoral toll-like receptor 9 (TLR9)
agonist, CMP-001, in combination with pembrolizumab can reverse
resistance to PD-1 inhibition in a phase Ib trial in subjects with
advanced melanoma. Cancer Res. 78 (13 Suppl):CT1442018.
|
|
58
|
Ribas A, Dummer R, Puzanov I, VanderWalde
A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J,
Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T
cell infiltration and improves anti-PD-1 immunotherapy. Cell.
174:1031–1032. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D,
Shen J and Ran ZH: Helicobacter pylori regulates TLR4 and
TLR9 during gastric carcinogenesis. Int J Clin Exp Pathol.
7:6950–6955. 2014.PubMed/NCBI
|
|
60
|
Gujar S, Pol JG, Kim Y, Lee PW and Kroemer
G: Antitumor benefits of antiviral immunity: An underappreciated
aspect of oncolytic virotherapies. Trends Immunol. 39:209–221.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yokoda R, Nagalo BM, Arora M, Egan JB,
Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH and Borad MJ: Oncolytic
virotherapy in upper gastrointestinal tract cancers. Oncolytic
Virother. 7:13–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
